Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Expanding JAK Inhibitor Arsenal Provides Additional Options Beyond Ruxolitinib in Myelofibrosis

December 16th 2024

Aaron Gerds, MD, discusses differences in molecular targets, efficacy, and toxicity profiles between available JAK inhibitors in myelofibrosis.

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

December 16th 2024

Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies undergoing allo-HCT.

Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer

December 16th 2024

The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.

Perioperative Pembrolizumab Plus Chemo Wins Approval in China for Resectable Stage II/III NSCLC

December 16th 2024

China’s NMPA has approved perioperative pembrolizumab plus chemotherapy for select patients with resectable non–small cell lung cancer.

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

December 14th 2024

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

December 14th 2024

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

T-DXd Preserves QOL, Neurological Function in HER2+ Metastatic Breast Cancer Irrespective of Brain Metastases

December 13th 2024

T-DXd displayed favorable HRQOL and neurological function results in HER2+ metastatic breast cancer regardless of the presence of brain metastases.

Camrelizumab/Chemo Could Represent New Neoadjuvant Option in Early or Locally Advanced TNBC

December 13th 2024

Neoadjuvant camrelizumab paired with chemotherapy significantly improved pCR over chemotherapy alone in early or locally advanced TNBC.

Orca-T Leads to Retrospective OS Improvement in High-Risk Hematologic Malignancies After Allo-HCT

December 13th 2024

Orca-T was retrospectively associated with improved OS in patients with high-risk hematologic malignancies undergoing allogeneic stem cell transplant.

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

December 13th 2024

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

CHMP Offers Positive Opinion for Imetelstat for Transfusion-Dependent Anemia in Lower-Risk MDS

December 13th 2024

The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

Dr Rozenblit on Pembrolizumab Outcomes by TMB Status in HR+ Metastatic Breast Cancer

December 13th 2024

Mariya Rozenblit, MD, discusses how genomic alterations and TMB influence the efficacy of immune checkpoint inhibitors in HR+ metastatic breast cancer.

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

December 13th 2024

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

FDA Grants Fast Track Designation to IMM-1-104 in NRAS+ Advanced Melanoma

December 12th 2024

The FDA has granted fast track designation to IMM-1-104 for the treatment of advanced melanoma.

China’s NMPA Grants Breakthrough Therapy Designation to Savolitinib Plus Osimertinib in EGFR+ NSCLC

December 12th 2024

Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

December 12th 2024

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis

December 12th 2024

Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.

Dr Ali on the S0221 Trial of Alternative Chemo Dosing Schedules in Breast Cancer

December 12th 2024

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer

December 11th 2024

Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer

December 11th 2024

Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.